Entera Bio (ENTX)
(Delayed Data from NSDQ)
$2.44 USD
-0.16 (-6.15%)
Updated May 17, 2024 04:00 PM ET
After-Market: $2.41 -0.03 (-1.23%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
ENTX 2.44 -0.16(-6.15%)
Will ENTX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ENTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ENTX
J&J (JNJ) to Boost Dermatology Portfolio With New Acquisition
Vanda (VNDA) Rises on Positive Data From Motion Sickness Study
ENTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Medical Stocks Lagging Entera Bio (ENTX) This Year?
Intellia's (NTLA) Q1 Earnings & Revenues Beat Estimates
Ironwood (IRWD) Q1 Earnings & Revenues Fall Shy of Estimates
Other News for ENTX
Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member
Entera Bio appoints Wagman as Key Clinical Advisor, SAB member
Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024
Entera Bio to present Phase 1 data from EB612 at ENDO 2024
Positive Outlook for Entera Bio with Buy Rating and Promising Pipeline Developments